BioNTech CMO discloses equity award holdings

BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales.

Rhea-AI Filing Summary

BioNTech SE’s Chief Medical Officer, Ozlem Tureci, filed an initial Form 3 disclosing existing equity-based awards, rather than new share purchases or sales. The filing lists option grants over 18,416, 25,459 and 9,306 underlying ordinary shares, phantom options over 7,112 and 14,664 shares, and 11,633 performance share units.

Footnotes explain that these options and PSUs generally vest in equal annual installments over four years and become exercisable four years after grant, subject to performance-based conditions tied to BioNTech’s share price and, for PSUs, its performance relative to the Nasdaq Biotechnology Index.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Tureci Ozlem

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Phantom Option	--	--	--
holding	Phantom Option	--	--	--
holding	Performance Share Unit	--	--	--

Holdings After Transaction: Option (right to buy) — 53,181 contracts (Direct); Phantom Option — 21,776 contracts (Direct); Performance Share Unit — 11,633 contracts (Direct)

Footnotes (7)

1. F1. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
2. F2. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.
3. F3. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.
4. F4. The exercise price of this option is EUR 75.91.
5. F5. The exercise price of this option is EUR 93.35.
6. F6. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.
7. F7. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BioNTech (BNTX) Chief Medical Officer report on this Form 3?

The filing reports existing equity awards held by BioNTech’s Chief Medical Officer, not new trades. It lists options, phantom options, and performance share units linked to ordinary shares, outlining the size of each award and their exercise and expiration dates.

Are there any BioNTech (BNTX) share purchases or sales in this Form 3?

No share purchases or sales are reported. The Form 3 only shows holdings of derivative awards such as options, phantom options, and performance share units, all classified as holdings with unknown transaction codes and neutral net buy‑sell direction.

What types of equity awards does Ozlem Tureci hold in BioNTech (BNTX)?

She holds options to buy ordinary shares, phantom options, and performance share units. Each award references underlying ordinary shares, with specific exercise prices and long-dated expiration dates, reflecting a mix of share-settled and cash-settled incentive instruments.

How do the phantom options for BioNTech (BNTX) Chief Medical Officer work?

Each phantom option entitles the holder to a cash payment equal to the difference between an exercise closing price and the exercise price. The exercise closing price is defined as the average ADS closing price over the ten trading days before exercise.

What performance conditions apply to BioNTech (BNTX) performance share units reported here?

Each performance share unit equals one ordinary share economically and vests annually over four years. Exercisability after four years depends on performance targets based on BioNTech’s share price versus the Nasdaq Biotechnology Index and continuous service through each relevant date.

Can BioNTech (BNTX) equity awards be settled in ADSs or cash?

Yes. Options may be settled in ordinary shares, American Depositary Shares, and/or cash at the supervisory board’s election. Performance share units can similarly be settled in one ordinary share, one ADS, cash, or another form equal to the economic share value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 05:36 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tureci Ozlem

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	05/22/2027(1)	05/22/2033	Ordinary Shares(2)	18,416	$113.94(3)	D
Option (right to buy)	08/26/2028(1)	08/26/2034	Ordinary Shares(2)	25,459	(3)(4)	D
Option (right to buy)	05/28/2029(1)	05/28/2035	Ordinary Shares(2)	9,306	(3)(5)	D
Phantom Option	05/12/2025(1)	05/12/2031	Ordinary Shares(6)	7,112	$185.23(3)	D
Phantom Option	05/31/2026(1)	05/31/2032	Ordinary Shares(6)	14,664	$152.1(3)	D
Performance Share Unit	05/27/2029(7)	05/27/2035	Ordinary Shares(7)	11,633	$0	D

Explanation of Responses:

1. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

2. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

3. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

4. The exercise price of this option is EUR 75.91.

5. The exercise price of this option is EUR 93.35.

6. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price.

7. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)